Replies to post #105140 on Biotech Values

[jbog]

Polly,

I'm sure you think the comment is absurb, but again we'll have to wait to find out because we don't have the data at this point.

Secondly, I guess you are agreeing that the original agreement is poor. I never said that the agreement wasn't the best deal they could get at the time, I only said it was bad.

Evidently, because they were able to do a better agreement the 2nd time around couldn't we assume the M-enox agreement is inferior.

[jbog]

Polly,


My Quote:
It certainly doesn't make any sense whatsoever UNLESS these two numbers are much closer to each other as a net payment to Momenta. The people here wouldn't agree at this point.

Your Humble Response:

I think that point is utterly absurd


Absurb?

Let's see. Sandoz earns 18.6% of gross sales for it normal run of the mill generic business. If M-Enox were to be reduced to a run of the mill generic and Momenta would receive 'single to low double digits royalties on sales'' it seems to me that Momenta would again be capturing in the area of 45% - 50% of the profits.

Not Absurb at all.